Malignant Neoplasm Of Gastrointestinal Tract News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Malignant neoplasm of gastrointestinal tract. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Malignant Neoplasm Of Gastrointestinal Tract Today - Breaking & Trending Today

Anesthesiologists' Experience Key in Complex GI Cancer Surgery?

email article
Complex gastrointestinal (GI) cancer surgery had less risk of postoperative adverse outcomes when supported by anesthesiologists performing a high annual volume of certain procedures, a large Canadian population-based study found.
Care by high-volume anesthesiologists was independently associated with 15% lower odds of combined 90-day major morbidity (including mortality) and readmission, after adjustment for patient case mix, institutional volume, and surgeon volume, reported Julie Hallet, MD, of the University of Toronto, and colleagues.
The primary outcome a composite of major 90-day morbidity (Clavien-Dindo 3-5) with readmission occurred in 36.3% of patients in the high-volume group (cutoff point of six or more procedures per year or ranking in the 75th percentile) and 45.7% of patients in the low-volume group, they stated in ....

United States , Karly Bilimoria , Julie Hallet , University Of Toronto , Feinberg School Of Medicine At Northwestern University , Elixhauser Comorbidity Index , Feinberg School , Northwestern University , Malignant Neoplasm Of Gastrointestinal Tract , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி ஹாலட் , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , ஃபைன்பெர்க் பள்ளி ஆஃப் மருந்து இல் வடமேற்கு பல்கலைக்கழகம் , ஃபைன்பெர்க் பள்ளி , வடமேற்கு பல்கலைக்கழகம் ,

New Anti-PD-1 Drug Active in Advanced Colon Cancer

This article is a collaboration between MedPage Today and:
Almost 40% of progressive, advanced gastrointestinal (GI) tumors with mismatch repair deficiency (dMMR) responded to the investigational anti-PD-1 agent dostarlimab, according to a preliminary clinical trial.
Overall, 38.7% of 106 patients responded to single-agent treatment with monoclonal antibody, including 36.2% of colorectal cancers (CRC) and 43.2% of all other tumors, which were primarily GI in origin. About three-fourths of patients had some degree of tumor shrinkage. During a median follow-up exceeding 1 year, median duration of response had yet to be reached.
Dostarlimab was well tolerated, as fewer than 10% of patients had ≥3 treatment-related adverse events (TRAEs), reported Thierry Andre, MD, of Sorbonne University and Saint-Antoine Hospital in Paris, at the Gastrointestinal Cancers Symposium virtual meeting. ....

France General , Charles Bankhead , Thierry Andre , John Krauss , University Of Michigan Medical Center , Sorbonne University , Medpage Today , Saint Antoine Hospital , Gastrointestinal Cancers Symposium , Michigan Medical Center , Malignant Neoplasm Of Gastrointestinal Tract , Neoplastic Disease , பிரான்ஸ் ஜநரல் , சார்லஸ் வங்கித் தலை , தியரி ஆண்ட்ரே , ஜான் க்ராஸ் , பல்கலைக்கழகம் ஆஃப் மிச்சிகன் மருத்துவ மையம் , சோர்போன் பல்கலைக்கழகம் , துறவி அன்டோயின் மருத்துவமனை , இரைப்பை குடல் புற்றுநோய்கள் சிம்போசியம் , மிச்சிகன் மருத்துவ மையம் ,